CCS1477

First-in-class p300/CBP inhibitor to treat specific cancers

  • 50+

    Epigenetic-related targets

    investigated over time by the CellCentric team

  • 1

    Drug prioritised, advanced

    CCS1477 in the clinic, to treat specific cancers

The target

CCS1477 is the first small molecule drug targeting twin proteins p300 and CBP. It is a small molecule, formulated as a capsule taken orally, in Phase I/II clinical trials.

p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.

CCS1477 is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.

CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.

Tweets by @cellcentric

Follow us

AACR 2021 online. CCS1477 was presented as a New Drug on the Horizon in 2019, Atlanta. Now in multiple strands of clinical trials. #AACR2021 pic.twitter.com/hj59FDLuUl

Targeting p300/CBP to treat cancer continues to gain interest. CellCentric’s first-in-class inhibitor CCS1477 in mutliple strands of clinical evaluation. pic.twitter.com/FQoU7jf7DW

New paper on abiraterone and p300/CBP @DrPhilKantoff et al. CellCentric’s p300/CBP inhibitor is in clinical trials +abi to treat prostate cancer. clincancerres.aacrjournals.org/content/27/7/2… pic.twitter.com/XqkNdluR4G